NEW YORK (GenomeWeb News) – MRIGlobal and Evogen today announced a five-year agreement to develop molecular diagnostic products targeting the in vitro and clinical molecular diagnostic markets.

Under the terms of the non-exclusive deal, MRIGlobal is providing product development services to Evogen, which was spun out of MRIGlobal in 2002. Services being provided include assay development, technology transfer, analytical and clinical studies, and commercialization support.

Financial terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.